English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Our starting platform was based on a heterologous BCG prime and MVA boost regimen delivering a common immunogen called HIVA. In this study, we have i) developed a BCG.HIVA strain containing an antibiotic free selection system (Cobra); ii) evaluated the specific HIV-1 immune responses induced after newborn BALB/c mice immunization with BCG.HIVA prime and MVA.HIVA.85A boost; iii) evaluated the specificTB immune responses induced after newborn BALB/c mice immunization with BCG.HIVA prime and MVA.HIVA.85A boost and iv) evaluated the influence of age on specific HIV-1 immune responses using the same vaccination schedule.

Pre-clinical development of BCG.HIVA(CAT) strain, an antibiotic-free selection strain for HIV-TB pediatric vaccine